Published in J Med Chem on May 12, 1995
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem (2001) 1.21
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists. J Med Chem (2008) 0.99
Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem (2013) 0.96
Activation and Desensitization of Rat A3-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides. Drug Dev Res (1998) 0.91
Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput Biol (2014) 0.91
Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol (2009) 0.87
Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochem Pharmacol (2007) 0.86
Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. ACS Med Chem Lett (2012) 0.86
Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. ACS Med Chem Lett (2011) 0.84
Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol (2001) 0.83
Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. Bioorg Med Chem (2005) 0.82
Partial agonists for A(3) adenosine receptors. Curr Top Med Chem (2004) 0.77
Chapter 13. A3 Adenosine Receptors. Annu Rep Med Chem (1) 0.75
A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS. Nucleosides Nucleotides (1) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine. Naunyn Schmiedebergs Arch Pharmacol (1980) 2.32
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A (1993) 2.08
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem (1992) 2.01
Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol (1980) 1.88
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol (1993) 1.78
Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res (1994) 1.62
Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem Pharmacol (1981) 1.59
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol (1993) 1.40
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem (1995) 1.26
Adenosine A3 receptors in mast cells. Trends Pharmacol Sci (1994) 1.21
Agonist activity of 2- and 5'-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. Biochem Pharmacol (1992) 1.11
Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res (1994) 1.00
Reversal of synaptic depression by serotonin at Aplysia sensory neuron synapses involves activation of adenylyl cyclase. Proc Natl Acad Sci U S A (1991) 0.95
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem (1991) 0.91
2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. Eur J Pharmacol (1988) 0.91
2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig. J Pharmacol Exp Ther (1993) 0.90
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. J Med Chem (1992) 0.89
Ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem (1986) 0.86
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. J Med Chem (1994) 0.86
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance. J Med Chem (1993) 0.85
Use of azido group in the synthesis of 5' terminal aminodeoxythymidine oligonucleotides. J Org Chem (1975) 0.85
5'-Deoxy-5'-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. Biochem Pharmacol (1988) 0.84
N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists. FEBS Lett (1987) 0.82
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev (1984) 2.38
Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol (1995) 2.19
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1996) 2.02
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem (2000) 1.65
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
The A1 adenosine receptor. Identification of the binding subunit by photoaffinity cross-linking. J Biol Chem (1985) 1.52
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. J Biol Chem (1987) 1.50
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther (2000) 1.43
Agonist derived molecular probes for A2 adenosine receptors. J Mol Recognit (1989) 1.43
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol (1995) 1.40
Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med (1984) 1.35
Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem (1992) 1.32
Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci (1983) 1.32
The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol (1991) 1.32
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J Med Chem (1998) 1.31
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem (1996) 1.31
Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J Neurosci (1997) 1.29
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem (1995) 1.26
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem (1995) 1.26
Adenosine receptors. Neuropharmacology (1995) 1.24
Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun (1996) 1.23
Chemical modification and irreversible inhibition of striatal A2a adenosine receptors. Mol Pharmacol (1992) 1.23
Characterization of the A1 adenosine receptor-adenylate cyclase system of cerebral cortex using an agonist photoaffinity ligand. J Neurochem (1986) 1.21
Mammalian beta-adrenergic receptors. Structural differences in beta 1 and beta 2 subtypes revealed by peptide maps. J Biol Chem (1983) 1.21
Photoaffinity cross-linked A1 adenosine receptor-binding subunits. Homologous glycoprotein expression by different tissues. J Biol Chem (1986) 1.20
The A1 adenosine receptor. Solubilization and characterization of a guanine nucleotide-sensitive form of the receptor. J Biol Chem (1985) 1.18
Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem (1993) 1.18
Measurement of the differential branching fraction and forward-backward asymmetry for B --> K(*)l+l-. Phys Rev Lett (2009) 1.17
Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi. Mol Pharmacol (1988) 1.17
Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. J Biol Chem (1994) 1.16
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem (1996) 1.13
Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem (1989) 1.13
125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol (1995) 1.13
Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr (2003) 1.11
Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol (1994) 1.11
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J Med Chem (1997) 1.09
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A (2000) 1.09
Demonstration of distinct agonist and antagonist conformations of the A1 adenosine receptor. J Biol Chem (1989) 1.09
Photoaffinity labelling of mammalian beta-adrenergic receptors: metal-dependent proteolysis explains apparent heterogeneity. Biochem Biophys Res Commun (1983) 1.09
Adenosine receptors: clinical implications and biochemical mechanisms. Prog Drug Res (1988) 1.08
Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein. J Pharmacol Exp Ther (1988) 1.08
Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells. Mol Pharmacol (1990) 1.07
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1999) 1.07
Precision measurement of charged pion and kaon differential cross sections in e+ e- annihilation at sqrt[s]=10.52 GeV. Phys Rev Lett (2013) 1.06
6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (1996) 1.06
The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett (2000) 1.06
Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B. Mol Pharmacol (1998) 1.05
Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem (1994) 1.05
Clinical relevance of exercise-induced S-T segment elevation. Am J Cardiol (1980) 1.04
Syphilis prevalence has rapidly decreased in South Korea. Sex Transm Infect (2003) 1.03
Chronic caffeine ingestion sensitizes the A1 adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest (1986) 1.02
Observation of anomalous upsilon(1S)pi+pi(-) and upsilon(2S)pi+pi(-) production near the upsilon(5S) resonance. Phys Rev Lett (2008) 1.02
Mammalian beta-adrenergic receptors. Distinct glycoprotein populations containing high mannose or complex type carbohydrate chains. J Biol Chem (1984) 1.01
Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res (1999) 1.01